ErlySign: Funding, Investors & Team (Sep 2026)
ErlySign creates home-based early detection test kits for life-threatening illnesses such as Oral cancer, Uterine cancer, Prostate cancer, Lung Cancer, Breast Cancer, Pancreatic Cancer, and others. By utilizing our advanced prognostics and diagnostics system, we have the ability to identify cancer prior to the emergence of any visible tumor or lesion. To put it simply, our tests can detect cancer at stage 0.
ErlySign has raised $2.0M across 3 funding rounds on record, the most recent a Seed of $1.9M announced in Jan 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ErlySign Company Profile and Key Stats
Latest funding round on record: Jan 2025.
ErlySign Funding Rounds
ErlySign raised $120k in a Seed announced in Jun 2023.
2 months later, an undisclosed round of $10k was announced in Aug 2023.
1.4 years later, a Seed of $1.9M was announced in Jan 2025.
ErlySign Founders and Leadership Team
No contact details are on record for this team yet.
ErlySign Funding Compared to Other Biotechnology Startups
ErlySign's latest round of $1.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ErlySign in Biotechnology and Nagpur
Companies Similar to ErlySign
4baseCare offers advanced genomic solutions in precision oncology to assist individuals with cancer. The…
Biodimension is offering biofabricated human tissues as an efficient animal alternative testing solutions to…
Pandorum Technologies Pvt. Ltd. is a Bangalore based biotechnology company with focus on tissue engineering…
PlasmaGen BioSciences is an Indian Bio-pharmaceutical organization specializing exclusively in Plasma Protein…
Cellarim is at the forefront of the biomanufacturing revolution. As a pioneer in the biotechnology business,…
ImmunitoAI is a life sciences (biotech) platform that leverages AI to revolutionize antibody discovery &…
Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell…
QRL Bioscience is a science and technology-focused company dedicated to finding solutions for diabetic foot…
Ivory improves the aging process by promoting sharper thinking and better living. They assist in the early…
Prantae Solutions is a biotechnology company that develops cost-effective technologies for uncommon and…
BrainSightAI is a software platform that uses MRI technology to improve accuracy in neurological and…
Agbiotech startup that envisions a world where good yields are an assurance and not a gamble despite the…
ErlySign Funding FAQs
What does ErlySign do?
ErlySign creates home-based early detection test kits for life-threatening illnesses such as Oral cancer, Uterine cancer, Prostate cancer, Lung Cancer, Breast Cancer, Pancreatic Cancer, and others. By utilizing our advanced prognostics and diagnostics system, we have the ability to identify cancer prior to the emergence of any visible tumor or lesion. To put it simply, our tests can detect cancer at stage 0.
How much funding has ErlySign raised?
ErlySign has raised $2.0M across 3 rounds on record. The most recent is a Seed of $1.9M announced in Jan 2025.
When did ErlySign last raise funding?
ErlySign's most recent funding round on record is a Seed of $1.9M, announced in Jan 2025.
Who founded ErlySign?
FundedIQ lists Shubhendra Singh Thakur (Founder) at ErlySign.
Where is ErlySign headquartered?
ErlySign is based in Nagpur, Maharashtra, India.
How many employees does ErlySign have?
ErlySign is in the 11-50 employee band.
How does ErlySign's funding compare to other Biotechnology startups?
ErlySign's latest round of $1.9M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ErlySign Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ErlySign is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.